HWAM
BHVN

Hennion & Walsh Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Hennion & Walsh Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-42,694
Closed -$6.45M – 826
2022
Q3 		$6.45M Sell
42,694
-1,781
-4% -$264K 0.42% 51
2022
Q2 		$6.48M Sell
44,475
-40,134
-47% -$5.13M 0.4% 56
2022
Q1 		$10M Sell
84,609
-2,738
-3% -$341K 0.53% 37
2021
Q4 		$12M Sell
87,347
-26,939
-24% -$3.43M 0.59% 32
2021
Q3 		$15.9M Buy
114,286
+924
+0.8% +$115K 0.83% 17
2021
Q2 		$11M Buy
113,362
+15,864
+16% +$1.29M 0.59% 29
2021
Q1 		$6.66M Buy
+97,498
New +$7.89M 0.4% 54

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Hennion & Walsh Asset Management's BHVN Position: Q4 2022 in Review

Hennion & Walsh Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 42,694 shares — an estimated $6.45M sold.

Hennion & Walsh Asset Management first reported a position in BHVN in Q1 2021 and held it in 7 quarters. The position peaked at $15.9M in Q3 2021. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Hennion & Walsh Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 42,694 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $6.45M.
  • Hennion & Walsh Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2021 and held it in 7 quarters.
  • Hennion & Walsh Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $15.9M in Q3 2021.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Hennion & Walsh Asset Management's 13F filing for Q4 2022, filed 12 Jan 2023.